Thank you for sharing!

Your article was successfully shared with the contacts you provided.
As many as 100 Pennie & Edmonds lawyers may join the New York office of Jones Day in the coming days and weeks as the 120-year-old intellectual property boutique prepares to shut down by Dec. 31. More than 25 Pennie & Edmonds partners have accepted offers to join Jones Day, and offers have been extended to about 75 associates, said Dennis W. LaBarre, partner-in-charge of Jones Day’s New York office. If all of the Pennie & Edmonds associates accept the offers, Jones Day will have well over 300 lawyers in its New York office, making it the firm’s largest. The 2,100-lawyer firm currently has its largest offices in Cleveland and Washington, D.C. The group receiving offers from Jones Day constitutes the bulk of the lawyers at Pennie & Edmonds’ New York headquarters, which at the end of September accounted for 133 of the firm’s 190 lawyers. A small number of Jones Day offers have been extended to lawyers in the firm’s Palo Alto, Calif., and Washington, D.C., offices, said LaBarre. John J. Normile, managing partner at Pennie & Edmonds, Tuesday hailed the arrangement as a boon to his firm’s lawyers. “We’re creating the best intellectual property group in the world,” he said. “We’ll obviously be the biggest and the best.” Neither Normile nor LaBarre would name any of the partners joining Jones Day, but sources familiar with the matter said, aside from Normile, the partners included litigation chair Brian Poissant and biotechnology and pharmaceutical group chair Laura A. Coruzzi. Normile said there was no firm deadline for associates pondering offers to join Jones Day. Though sources at Pennie & Edmonds had earlier expressed fear that Jones Day might offer some lawyers only limited terms of employment, LaBarre said all offers to join Jones Day from Pennie & Edmonds were normal offers of full-time employment. Normile would not say which or how many lawyers had either declined offers to join Jones Day or had failed to receive such offers. In a memo Pennie & Edmonds’ management circulated last week, associates and support staff were informed that if they failed to receive offers from Jones Day, they would be terminated on Dec. 31. Other firms — most significantly Morgan, Lewis & Bockius — have already scooped up a number of Pennie & Edmonds partners. At the beginning of the month, Morgan Lewis hired most of the lawyers in Pennie & Edmonds’ 32-lawyer Palo Alto office and one partner in Washington, D.C. Morgan Lewis said Tuesday it was on the verge of hiring one partner in Pennie & Edmonds’ New York office as well. Last week, New York trademark boutique Fross Zelnick Lehrman & Zissu hired Pennie & Edmonds partners David Weild and Maria A. Scungio, while Matthew Langer joined the New York office of Boston-based Hale & Dorr. Normile, who had previously denied his firm was interested in a merger and had argued that standalone IP boutiques could thrive in competition against general practice firms, Tuesday said “it certainly seems to be the trend” that general practice firms will take a larger and larger share of the IP practice. Among the advantages, he said, are the ability to interact with a wide variety of corporate, tax and other transactional lawyers. He also noted that Jones Day enjoyed a particularly strong reputation with regard to its litigation practices. But he said he also expected other IP boutiques to continue to do well. MALPRACTICE SUIT As Pennie & Edmonds lawyers decide what their next step may be, Manhattan Supreme Court Justice Charles Ramos is also weighing the firm’s future. Tuesday, he heard oral arguments on Pfizer Inc.’s motion for summary judgment in its malpractice suit against the law firm. Pfizer, once Pennie & Edmonds’ largest client, sued the firm for procuring a patent for the University of Rochester that formed the basis for an infringement suit against the pharmaceutical maker over its blockbuster drug Celebrex. Tuesday, Pfizer’s lawyer, Richard Seltzer of Kaye Scholer, called the patent “a loaded gun [Pennie & Edmonds] handed to the University of Rochester to shoot Pfizer.” But Pennie & Edmonds’ lawyer, Jay G. Safer of LeBeouf, Lamb, Greene & MacRae, said there “never was an awareness there was any conflict,” in part because the scientific and technical language of the patents did not appear to point to an obvious collision of interests. Justice Ramos declined to rule from the bench but made clear he was uncomfortable with granting summary judgment in the case. “I’m not a scientist and neither are you,” he told the lawyers before him. Ramos also said that while Pennie & Edmonds might be guilty of ethical misconduct, he feared that asking the firm to disgorge millions in legal fees might be an extreme punishment. “We don’t want them to be going 60,” he said. “We want them going 90 with the beer can out the window.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.